Show simple item record

dc.contributor.authorBrown, Ashley N.
dc.contributor.authorStrobel, Gary
dc.contributor.authorHanrahan, Kaley C.
dc.contributor.authorSears, Joe
dc.date.accessioned2022-06-28T17:48:54Z
dc.date.available2022-06-28T17:48:54Z
dc.date.issued2021-03
dc.identifier.citationBrown, A.N.; Strobel, G.; Hanrahan, K.C.; Sears, J. Antiviral Activity of the PropylamylatinTM Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions. Viruses 2021, 13, 415. https://doi.org/ 10.3390/v13030415en_US
dc.identifier.issn1999-4915
dc.identifier.urihttps://scholarworks.montana.edu/xmlui/handle/1/16889
dc.description.abstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of novel coronavirus disease 2019 (COVID-19), has become a severe threat to global public health. There are currently no antiviral therapies approved for the treatment or prevention of mild to moderate COVID-19 as remdesivir is only approved for severe COVID-19 cases. Here, we evaluated the antiviral potential of a Propylamylatin formula, which is a mixture of propionic acid and isoamyl hexanoates. The Propylamylatin formula was investigated in gaseous and liquid phases against 1 mL viral suspensions containing 105 PFU of SARS-CoV-2. Viral suspensions were sampled at various times post-exposure and infectious virus was quantified by plaque assay on Vero E6 cells. Propylamylatin formula vapors were effective at inactivating infectious SARS-CoV-2 to undetectable levels at room temperature and body temperature, but the decline in virus was substantially faster at the higher temperature (15 min versus 24 h). The direct injection of liquid Propylamylatin formula into viral suspensions also completely inactivated SARS-CoV-2 and the rapidity of inactivation occurred in an exposure dependent manner. The overall volume that resulted in 90% viral inactivation over the course of the direct injection experiment (EC90) was 4.28  ls. Further investigation revealed that the majority of the antiviral effect was attributed to the propionic acid which yielded an overall EC90 value of 11.50  ls whereas the isoamyl hexanoates provided at most a 10-fold reduction in infectious virus. The combination of propionic acid and isoamyl hexanoates was much more potent than the individual components alone, suggesting synergy between these components. These findings illustrate the therapeutic promise of the Propylamylatin formula as a potential treatment strategy for COVID-19 and future studies are warranted.en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleAntiviral Activity of the PropylamylatinTM Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensionsen_US
dc.typeArticleen_US
mus.citation.extentfirstpage1en_US
mus.citation.extentlastpage14en_US
mus.citation.journaltitleVirusesen_US
mus.citation.volume13en_US
mus.identifier.doi10.3390/v13030415en_US
mus.relation.collegeCollege of Agricultureen_US
mus.relation.departmentPlant Sciences & Plant Pathology.en_US
mus.relation.universityMontana State University - Bozemanen_US
mus.data.thumbpage8en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license
Except where otherwise noted, this item's license is described as © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license

MSU uses DSpace software, copyright © 2002-2017  Duraspace. For library collections that are not accessible, we are committed to providing reasonable accommodations and timely access to users with disabilities. For assistance, please submit an accessibility request for library material.